Investors / United States / The Column Group
The Column Group
Venture capital · San Francisco, CA, United States · North America
The Column Group is a venture capital firm focused on the life sciences industry. It builds and invests in biotechnology companies, supporting them from early-stage drug discovery through exit.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechnologytherapeuticsdrug discoverycompany formation
Your fit with The Column Group
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsThe Column Group lists 37 checked portfolio companies on its own site and is named in 11 funding rounds, 9 of them as lead. Its most frequent entry is Growth, 44% of the companies with a known first round. Its largest themes are Healthcare & Biotech (95%), Fintech (3%) and E-commerce & Marketplaces (3%). 93% of its companies are based in United States. It invests most often alongside Foresite Capital, Casdin Capital and Nextech Invest.
Counts come from funding rounds that name The Column Group, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not The Column Group's whole history. Rounds on record name 10 companies; its own site lists 37. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 22% |
| Series B | 33% |
| Growth | 44% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 1 | 1 |
| '24 | 0 | 0 |
| '25 | 2 | 1 |
| '26 | 8 | 7 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 75th | 37 companies |
| Recent activity | 94th | 9 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 94th | 24% of companies confirmed by a round |
| Sector focus | 97th | 95% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Foresite Capital | 7 |
| Casdin Capital | 6 |
| Nextech Invest | 6 |
| RA Capital | 6 |
| Lux Capital | 4 |
| TCG Crossover | 4 |
| Atlas Venture | 3 |
| Frazier Life Sciences | 3 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers3492%
- No longer answers00%
- Points to another company38%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 95% | 15% |
| Fintech | 3% | 12% |
| E-commerce & Marketplaces | 3% | 6% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Foresite Capital
Compare The Column Group head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with The Column Group| Date | Company | Stage |
|---|---|---|
| 23 Oct 2026 | Series C+ Led | |
| 1 Oct 2026 | Series C+ Led | |
| 16 Sept 2026 | Series C+ Led | |
| 20 Aug 2026 | Debt Led | |
| 12 Aug 2026 | Series B Led | |
| 22 Jun 2026 | Series B Led | |
| 21 Apr 2026 | Series A Led | |
| 5 Mar 2026 | Series B |
Round details for The Column Group
Amounts, full round histories and every co-investor in The Column Group's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
37 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| A2 Biotherapeutics is advancing a cell engineering platform to create precision CAR T-cell therapies for cancer and other diseases. | Healthcare & Biotech | Portfolio page | ||
| Accent Therapeutics develops small molecule therapeutics for patients living with cancer | Healthcare & Biotech | Portfolio page | ||
| Arcus Biosciences creates medicines by advancing validated biology with exceptional chemistry. | Healthcare & Biotech | Portfolio page | ||
| Atavistik Bio is a clinical-stage biotechnology company developing innovative therapies for patients with serious hematologic diseases. | Healthcare & Biotech | Dec 2025Series B · 2 rounds | Page + round | |
| Cajal Therapeutics is developing novel medicines for serious diseases, including anemias of inflammation, neurodegenerative diseases, and other iron-related disorders. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Circle Pharma harnesses the power of macrocycles to transform the treatment of cancer. | Healthcare & Biotech | Sept 2026Series C+ | Page + round | |
| Eikon Therapeutics is a company with offices in multiple locations. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| Hexagon Bio discovers and develops novel antibody-drug conjugate payload mechanisms for cancer therapy | Healthcare & Biotech | Oct 2026Series C+ | Page + round | |
| InduPro develops proximity-based therapeutics by manipulating protein interactions on the cell surface to treat diseases. | Healthcare & Biotech | Aug 2026Series B | Page + round | |
| Judo Bio develops oligonucleotide medicines delivered to the kidney for treating systemic and renal diseases. | Healthcare & Biotech | Portfolio page | ||
| Kenai Therapeutics is a clinical-stage biotechnology company that advances cell therapies and gene-modified medicines for the treatment of neurological conditions. | Healthcare & Biotech | Portfolio page | ||
| Kimia develops and uses technology to accelerate the discovery of novel drugs. | Healthcare & Biotech | Portfolio page | ||
| Lyterian Therapeutics develops medicines for patients by co-opting protein homeostatic mechanisms to regulate genetically-validated targets. | Healthcare & Biotech | Portfolio page | ||
| Monimoi Therapeutics is delivering transformative therapies by harnessing the potential of covalent medicines and chemical proteomics for cancer treatment. | Healthcare & Biotech | Portfolio page | ||
| Mundi provides trade finance services, including invoice financing and lines of credit, to businesses in Mexico. | FintechE-commerce & Marketplaces | Aug 2026Debt | Funding round | |
| Neurona Therapeutics develops cell therapies for targeted repair of dysfunctional neural circuits underlying chronic diseases | Healthcare & Biotech | Portfolio page | ||
| The company develops life-changing medicines by leveraging insights into human biology. | Healthcare & Biotech | Portfolio page | ||
| Nilo Therapeutics develops treatments for autoimmune and inflammatory diseases by targeting neural circuits | Healthcare & Biotech | Oct 2025Series A | Page + round |
About this data
site last read 13 Nov 2026- Site
- thecolumngroup.com
- Last read
- 13 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 6 Jan 2023
- Companies checked
- 37
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get The Column Group's profile as data
Pull The Column Group's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/thecolumngroup.com
# also
GET /v1/firms/thecolumngroup.com/portfolio
GET /v1/firms/thecolumngroup.com/coinvestors
GET /v1/firms/thecolumngroup.com/news